Salutas Pharma Gmbh Pharmaceutical Import Profile — Germany (DGFT 2022–2026)

Name: Salutas Pharma Gmbh Pharmaceutical Import Records from India — 3 Products, $5.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Salutas Pharma Gmbh — Pharmaceutical Importer Profile (2026) | 3 Products, $5.3M Trade | TransData Nexus

Salutas Pharma Gmbh

Pharmaceutical Importer · Germany · Respiratory Focus · $5.3M Total Trade · DGFT Verified

Salutas Pharma Gmbh is a pharmaceutical importer based in Germany with a total trade value of $5.3M across 3 products in 2 therapeutic categories. Based on 129 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Salutas Pharma Gmbh sources from 7 verified Indian suppliers, with Cipla Limited accounting for 50.4% of imports.

Salutas Pharma Gmbh — Import Portfolio & Supplier Network

Salutas Pharma Gmbh import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Salutas Pharma Gmbh?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$4.6M	385	50.4%
Sandoz Private Limited	$2.0M	64	21.5%
Usv Private Limited	$1.0M

What Formulations Does Salutas Pharma Gmbh Import?

Formulation	Value	Ships
Furosemide TAB 40MG in91 sh eu 02	$438.2K	10
Airflusal (fluticasone 125mcg and	$389.9K	8
Airflusal 25/250 mdi inhaler	$300.0K	6
Airflusal (fluticasone 250 MCG and	$300.0K	6
Furosemide TAB 40MG in91 sh eu 02 material no -	$254.6K	7
Material no - 42024057 furosemide TAB 40MG in91 sh eu	$227.0K	6
Gliclazide mr TAB 60MG 30 sandoz	$199.0K	4
Furosemide TAB 125MG in91 sh eu 01	$158.8K	6
Furosemide TAB 500MG in91 sh eu 01	$150.0K	3
Finasteride tablets 5 mgpack	$137.8K	6
Airflusal (fluticasone 125mcg and salmeterol 25mcg)	$131.0K	3
Airflusal 25/125 mdi inhaler (fluticasone propionate 125 MCG and salmeterol xinafoate 25 MCG inhaler)	$127.2K	3
Mertformin 1000 MG pr tabs 6x10s it (qty: 51620 car) batch no. 18037424, 18037431, 18037425	$103.6K	3
Gliclazide mr TAB 60MG 90 sandoz	$100.0K	2
Airflusan sprayhaler 25/250mcg	$100.0K	2

Salutas Pharma Gmbh imports 307 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fluticasone	Respiratory	$2.1M	42	1.0%	8
2	Furosemide	Diuretics	$2.1M	64	2.9%	5
3	Salmeterol	Respiratory	$1.1M	23	1.6%	11

Salutas Pharma Gmbh imports 3 pharmaceutical products across 2 categories into Germany totaling $5.3M.

Salutas Pharma Gmbh — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Salutas Pharma GmbH is a German pharmaceutical company specializing in the development, manufacturing, and distribution of pharmaceutical products. Established in 1993, the company operates as a subsidiary of Sandoz, which is part of the Novartis Group. Headquartered at Otto-von-Guericke-Allee 1, 39179 Barleben, Germany, Salutas Pharma GmbH employs approximately 1,500 individuals across its facilities in Barleben, Osterweddingen, and Magdeburg. (vev.icu) The company offers a diverse range of products, including ointments, creams, gels, and solid oral medications, with a notable focus on highly effective drugs for cancer therapy.

2Distribution Network

Salutas Pharma GmbH operates a robust distribution network within Germany and internationally. Its primary manufacturing and logistics centers are located in Barleben, Osterweddingen, and Magdeburg, which are among the most modern and efficient pharmaceutical production and logistics centers in Europe. (vev.icu) The company employs approximately 1,500 individuals across these facilities, indicating a substantial operational scale. While specific details about warehouse locations and logistics capabilities beyond Germany are not publicly disclosed, the company's extensive workforce and advanced facilities suggest a well-established distribution network capable of serving both domestic and international markets.

3Industry Role

Salutas Pharma GmbH plays a significant role in Germany's pharmaceutical supply chain as a manufacturer and distributor of pharmaceutical products. As a subsidiary of Sandoz, it contributes to the production and distribution of a wide range of pharmaceutical formulations, including generic drugs and specialized treatments. The company's focus on high-quality manufacturing and efficient distribution aligns with its role in ensuring the availability of essential medications within Germany and potentially in other European markets.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Salutas Pharma Gmbh

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Salutas Pharma GmbH's sourcing strategy exhibits a high degree of concentration, with a total import value from India amounting to $5.3 million USD across 129 shipments. The top five products imported—Fluticasone, Furosemide, and Salmeterol—account for 100% of the company's imports from India, indicating a complete reliance on these specific formulations. This sourcing pattern suggests a strategic focus on these products, likely due to their therapeutic importance and market demand. However, the lack of diversification in sourcing could pose risks related to supply chain disruptions, price fluctuations, or regulatory changes affecting these specific products.

2Supply Chain Resilience

Salutas Pharma GmbH's supply chain resilience is closely tied to its sourcing strategy from India. The company's complete reliance on a limited number of products from a single country introduces potential vulnerabilities, such as exposure to geopolitical risks, regulatory changes, or disruptions in manufacturing. The absence of backup suppliers for these specific products further amplifies this risk. Additionally, the company's focus on a narrow range of formulations may limit its ability to adapt to changing market demands or therapeutic advancements. To enhance supply chain resilience, diversifying the supplier base and expanding the product portfolio could be considered.

Importing Pharmaceuticals into Germany — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Germany

1Regulatory Authority & Framework

In Germany, the primary regulatory authority overseeing pharmaceutical imports and marketing is the Federal Institute for Drugs and Medical Devices (BfArM). The key legislation governing pharmaceutical imports includes the German Medicines Act (AMG), which outlines the requirements for the import, distribution, and marketing of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from BfArM, which assesses the quality, safety, and efficacy of the products. This process ensures that imported generics meet the stringent standards set for the German market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Germany necessitate that manufacturers and importers hold a valid wholesale distribution authorization issued by the competent authority. Additionally, imported products must be accompanied by a Good Manufacturing Practice (GMP) certificate, which can be recognized from countries with equivalent standards, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S). This ensures that imported pharmaceuticals adhere to the high-quality manufacturing standards required in Germany.

Quality & Labeling

Salutas Pharma Gmbh — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Salutas Pharma GmbH's product strategy focuses on the respiratory and diuretics therapeutic categories, with imports primarily consisting of Fluticasone, Furosemide, and Salmeterol. This focus aligns with the company's expertise in manufacturing and distributing these specific formulations. The market demand for these products is driven by the prevalence of respiratory and cardiovascular conditions in Germany, necessitating effective treatments. By concentrating on these therapeutic areas, Salutas Pharma GmbH aims to address significant healthcare needs and maintain a competitive edge in the market.

2Sourcing Profile

Salutas Pharma GmbH's sourcing strategy is centered on importing generic formulations from India, particularly in the respiratory and diuretics categories. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. The company's preference for specific formulations indicates a strategic choice to maintain product quality and consistency. India's role as a key supplier aligns with Salutas Pharma GmbH's objectives to provide effective and affordable medications to the German market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Salutas Pharma Gmbh

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Salutas Pharma GmbH, particularly those offering high-quality formulations in the respiratory and diuretics therapeutic categories. The company's concentrated sourcing pattern suggests a preference for stability and reliability in supply chains, which could be advantageous for suppliers who can consistently meet quality and regulatory standards. However, the limited diversification in Salutas Pharma GmbH's sourcing strategy may also indicate a cautious approach to introducing new suppliers, necessitating a strong value proposition and proven track record for potential partners.

2Requirements & Qualifications

Indian exporters seeking to supply Salutas Pharma GmbH and the German market must ensure that their products comply with EU GMP standards and possess valid GMP certificates recognized by German authorities. Additionally, obtaining a wholesale distribution authorization from the competent German authority is essential. Products must meet all quality, safety, and efficacy standards set by German regulations, including appropriate labeling in German and adherence to serialization mandates.

3How to Approach

Frequently Asked Questions — Salutas Pharma Gmbh

What products does Salutas Pharma Gmbh import from India?

Salutas Pharma Gmbh imports 3 pharmaceutical products across 2 categories. Top imports: Fluticasone ($2.1M), Furosemide ($2.1M), Salmeterol ($1.1M).

Who supplies pharmaceuticals to Salutas Pharma Gmbh from India?

Salutas Pharma Gmbh sources from 7 verified Indian suppliers. The primary supplier is Cipla Limited (50.4% of imports, $4.6M).

What is Salutas Pharma Gmbh's total pharmaceutical import value?

Salutas Pharma Gmbh's total pharmaceutical import value from India is $5.3M, based on 129 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Salutas Pharma Gmbh focus on?

Salutas Pharma Gmbh imports across 2 categories. The largest: Respiratory (61.2%), Diuretics (38.8%).

Get Full Salutas Pharma Gmbh Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.